# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM ASSAY ONLY TEMPLATE

A. 510(k) Number: K181871   
B. Purpose for Submission: Adding previously cleared assays on a new instrument platform   
C. Measurand: IgG autoantibodies specific to tissue transglutaminase (tTG) IgA autoantibodies specific to gliadin IgG autoantibodies specific to gliadin   
D. Type of Test: Automated semi-quantitative solid-phase fluoroimmunoassays   
E. Applicant: Phadia AB   
F. Proprietary and Established Names: EliA Celikey IgG Immunoassay EliA GliadinDP IgA Immunoassay EliA GliadinDP IgG Immunoassay

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 6 . 5 6 6 0$ , Multiple autoantibodies immunological test system 21 CFR $\ S 8 6 6 . 5 7 5 0$ , Radioallergosorbent (RAST) Immunological Test System

2. Classification: Class II

3. Product code: MVM, Autoantibodies, endomysial (tissue transglutaminase) MST, Autoantibodies, gliadin

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended uses:

EliA Celikey IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to tissue transglutaminase (tTG) in human serum and EDTA-plasma. EliA Celikey IgG is based on recombinant human tissue transglutaminase as antigen and is useful as an aid in the clinical diagnosis of patients with celiac disease in conjunction with other laboratory and clinical findings. EliA Celikey IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

EliA GliadinDP IgA is intended for the in vitro semi-quantitative measurement of IgA antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA GliadinDP IgA uses the EliA IgA method on the instrument Phadia 2500/5000.

EliA GliadinDP IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA GliadinDP IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

2. Indications for use: Same as intended uses

3. Special conditions for use statement: For prescription use only

4. Special instrument requirements: For use on the Phadia 2500 and Phadia5000 instruments

# I. Device Description:

The method-specific reagents are identical with K062583 (EliA Celikey IgG) and K093459 (EliA GliadinDP IgA and EliA GliadinDP IgG), but are filled in containers specific for the Phadia 2500/5000 instrument. Each device consists of the folloing:

# EliA Assay-specific Reagents:

EliA Celikey IgG Wells are coated with human recombinant tissue transglutaminase (tTG), ready to use EliA GliadinDP IgA Wells are coated with synthetic deamidated gliadin peptides, ready to use · EliA GliadinDP IgG Wells are coated with synthetic deamidated gliadin peptides, ready to use

# EliA Method-specific Reagent:

· EliA Sample Diluent: PBS containing BSA, detergent and $0 . 0 9 5 \%$ (w/v) sodium azide ready to use

EliA IgG reagents (required for EliA Celikey IgG and EliA GliadinDP IgG):

EliA IgG Conjugate 50 or 200: $\beta$ -Galactosidase labeled anti- $\mathrm { \cdot I g G }$ (mouse monoclonal antibodies) in PBS containing BSA and $0 . 0 6 \%$ (w/v) sodium azide, ready to use EliA IgG Calibrator Strips: Human IgG (0, 4, 10, 20, 100, $6 0 0 \mu \mathrm { g / L }$ ) in PBS containing BSA, detergent and $0 . 0 9 5 \%$ (w/v) sodium azide, ready to use EliA IgG Curve Control Strips: Human IgG $( 2 0 \mu \mathrm { g / L } )$ in PBS containing BSA, detergent and $0 . 0 9 5 \%$ (w/v) sodium azide, ready to use EliA IgG Calibrator Well: Coated with mouse monoclonal antibodie), ready to use

EliA IgA reagents (required for EliA GliadinDP IgA):

EliA IgA Conjugate 50 or 200: $\beta$ -Galactosidase labeled anti-IgA (mousemonoclonal antibodies) in PBS containing BSA and $0 . 0 6 \%$ (w/v) sodium azide, ready to use · EliA IgA Calibrator Strips: Human IgA (0, 0.3, 1.5, 5, 15, $8 0 ~ \mu \ g / \mathrm { L }$ ) in PBS containing BSA, detergent and $0 . 0 9 5 \%$ (w/v) sodium azide, ready to use EliA IgA Curve Control Strips: Human IgA $( 2 0 \mu \mathrm { g / L } )$ in PBS containing BSA, detergent and $0 . 0 9 5 \%$ $\mathrm { ( w / v ) }$ sodium azide, ready to use EliA IgA Calibrator Well: Coated with mouse monoclonal antibodies, ready to use

The EliA reagents are available as modular packages, each purchased separately. All packages are required to carry out EliA Celikey $\mathrm { I g G }$ , EliA GliadinDP IgA, and EliA GliadinDP IgG tests.

# J. Substantial Equivalence Information:

1. Predicate device names and Predicates: EliA Celikey IgG on Phadia 250 instrument, K062583 EliA GliadinDP IgA on Phadia 250 instrument, K093459 EliA GliadinDP IgG on Phadia 250 instrument,K093459

2. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device*Phadia 2500/5000EliA Celikey IgG andEliA GliadinDP IgA/IgG(K181871)</td><td colspan="1" rowspan="1">PredicatePhadia 250EliA Celikey IgG (K062583)EliA GliadinDP IgA/IgG(K093459)</td></tr><tr><td colspan="1" rowspan="1">Intended Use:EliA Celikey IgG</td><td colspan="1" rowspan="1">EliA Celikey IgG is intended forthe in vitro semi-quantitativemeasurement of IgG antibodiesdirected to tissuetransglutaminase (tTG) in humanserum and EDTA-plasma. EliACelikey IgG is based onrecombinant human tissuetransglutaminase as antigen andis useful as an aid in the clinical</td><td colspan="1" rowspan="1">EliA Celikey IgG is intendedfor the in vitro semi-quantitative measurement ofIgG antibodies directed totissue transglutaminase (tTG)in human serum and plasma.EliA Celikey IgG is based onrecombinant human tissuetransglutaminase as antigenand is useful as an aid in the</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device*Phadia 2500/5000EliA Celikey IgG andEliA GliadinD IgA/IgG(K181871)</td><td colspan="1" rowspan="1">PredicatePhadia 250EliA Celikey IgG (K062583)EliA GliadinDP IgA/IgG(K093459)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">diagnosis of patients with celiacdisease in conjunction with otherlaboratory and clinical findings.EliA Celikey IgG uses the EliAIgG method on the instrumentPhadia 2500/5000.</td><td colspan="1" rowspan="1">clinical diagnosis of patientswith Celiac disease. EliACelikey IgG uses the EliAIgG method on the instrumentImmunoCAP 250*.(* Former name of Phadia250)</td></tr><tr><td colspan="1" rowspan="1">Intended Use:EliA GliadinDPIgA/IgG</td><td colspan="1" rowspan="1">EliA GliadinDP IgA/IgG isintended for the in vitro semi-quantitative measurement ofIgA/IgG antibodies directed togliadin in human serum orplasma (Li-heparin, EDTA) toaid in the diagnosis of celiacdisease in conjunction with otherlaboratory and clinical findings.EliA GliadinDP IgA/IgG uses theEliA IgA/IgG method on theinstrument Phadia 2500/5000.</td><td colspan="1" rowspan="1">EliA GliadinDP IgA/IgG isintended for the in vitro semi-quantitative measurement ofIgA/IgG antibodies directedto gliadin in human serum andplasma (heparin, EDTA,citrate) to aid in the diagnosisof celiac disease inconjunction with otherlaboratory and clinicalfindings. EliA GliadinDPIgA/IgG uses the EliAIgA/IgG method on theinstrument Phadia 250.</td></tr><tr><td colspan="1" rowspan="1">Signal</td><td colspan="1" rowspan="1">Immuno-fluorescencemeasurement</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay type</td><td colspan="1" rowspan="1">ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Type of test</td><td colspan="1" rowspan="1">Semi-quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antigen:Celikey IgGGliadinDPIgA/IgG</td><td colspan="1" rowspan="1">Human recombinanttransglutaminase (tTG)Synthetic deaminated gliadinpeptides</td><td colspan="1" rowspan="1">SameSame</td></tr><tr><td colspan="1" rowspan="1">Common,dedicatedPhadia reagents</td><td colspan="1" rowspan="1">Same. Introduction of newarticle numbers for DevelopmentSolution, Stop Solution andWashing Solution is only due tolarger filling volumes which arerequired for the biggerinstruments Phadia 2500/5000</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Time to 1st result</td><td colspan="1" rowspan="1">About two hours</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detectionantibody</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td>Item</td><td>Device *Phadia 2500/5000 EliA Celikey IgG and EliA GliadinDP IgA/IgG (K181871)</td><td>Predicate Phadia 250 EliA Celikey IgG (K062583) EliA GliadinDP IgA/IgG</td></tr><tr><td>(conjugate): Celikey IgG and GliadinDP IgG</td><td>B-Galactosidase anti-IgG, mouse monoclonal antibodies</td><td>(K093459) Same</td></tr><tr><td>GliadinDP IgA</td><td>B-Galactosidase anti-IgA, mouse monoclonal antibodies</td><td>Same</td></tr><tr><td>Incubation temperature</td><td>37°</td><td>Same</td></tr><tr><td>Sample matrix: Celikey IgG</td><td>Serum and plasma (EDTA)</td><td>Same</td></tr><tr><td>Calibrator strips: Celikey IgG and GliadinDP IgG</td><td>Human IgG 0, 4, 10, 20, 100, 600 µg/L</td><td>Same</td></tr><tr><td>GliadinDP IgA</td><td>Human IgA 1, 0.3, 1.5, 5, 15, 80 µg/L</td><td>Same</td></tr><tr><td>Control: Celikey IgG and Gliai adDP IgG</td><td>EliA IgG curve control strips, 20 μg/L</td><td>Same</td></tr><tr><td>GliadinDP IgA</td><td>EliA IgA curve control strips, 5μg/L</td><td>Same</td></tr><tr><td>Cutt-off</td><td>Negative &lt;7 Equivocal 7-10</td><td>Same</td></tr><tr><td>Assay set-up</td><td>Positive &gt;10 Random access</td><td>Same</td></tr><tr><td>Result calculation software</td><td>Phadia Information Data Manager (IDM)</td><td>Same</td></tr><tr><td>Sample volume</td><td>90 μL (20 μL of non-diluted sample)</td><td>Same</td></tr><tr><td>Conjugate</td><td>90 μL</td><td>Same</td></tr><tr><td rowspan="2">volume Development solution</td><td>90 μL</td><td>Same</td></tr><tr><td>Same</td><td></td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Phadia 2500/5000</td><td colspan="1" rowspan="1">Phadia 250</td></tr><tr><td colspan="1" rowspan="1">Sample matrix:GliadinDP IgA/IgG</td><td colspan="1" rowspan="1">Serum and plasma (Li-heparin,EDTA)</td><td colspan="1" rowspan="1">Serum and plasma (Li-heparin, EDTA, citrate )</td></tr><tr><td colspan="1" rowspan="1">Measuring range:Celikey IgGGli adDP IgAGliadinDPIgG</td><td colspan="1" rowspan="1">LoQ to upper limit1.7 to 227 EliA U/mL0.4 to 142EliA U/mL1.4 to 302 EliA U/mL</td><td colspan="1" rowspan="1">LoD to upper limit0.6 to ≥ 600 EliA U/mL0.1 to ≥ 142 EliA U/mL0.4 to ≥ 132 EliA U/mL</td></tr><tr><td colspan="1" rowspan="1">Sample dilution,pipets</td><td colspan="1" rowspan="1">Disposable Pipette Tips in Racksfor pipetting samples in DilutionWell</td><td colspan="1" rowspan="1">Steel pipette to dilute thesamples in Dilution Plates</td></tr><tr><td colspan="1" rowspan="1">Risk forcarry-over</td><td colspan="1" rowspan="1">When running EliA tests on thePhadia 2500/5000 instruments,there is no need for this warningstatement because theseinstruments use disposable tipsfor pipetting samples and aseparate pipette for theconjugate, and carry-over fromsamples to conjugate isimpossible.</td><td colspan="1" rowspan="1">The warning "DO NOTREUSE" in the Phadia 250DFU for EliA Conjugates isdue to the fact that a low riskof conjugate contamination bycarry-over from samples wasidentified. In order to reducethe risk, the single usestatement for the conjugatewas included in the Phadia250 DFU.</td></tr><tr><td colspan="1" rowspan="1">Loading of EliACarriers</td><td colspan="1" rowspan="1">The Phadia 2500/5000instruments do not have LoadingTray. The EliA carriers areloaded into racks which aredirectly transferred to the cooledstorage compartment</td><td colspan="1" rowspan="1">EliA carriers are loadedmanually on the Loading Trayfrom where they can beprocessed directly ortransferred to the cooledstorage compartment.</td></tr><tr><td colspan="1" rowspan="1">Barcode reader</td><td colspan="1" rowspan="1">On the Phadia 2500/5000 thereagents are on a moving beltwhich conveys them past thebarcode reader. The lot-specificinformation will be readautomatically by the instrumentduring loading.</td><td colspan="1" rowspan="1">The Phadia 250 instrumenthas a built-in barcode readerat the front of the instrument,but the operator needs to scanthe barcodes manually byshowing the reagents to thebarcode reader. Alternatively,the operator can also enter thecharacters below the barcodemanually.</td></tr><tr><td colspan="1" rowspan="1">Process time /Time to patientresult</td><td colspan="1" rowspan="1">Phadia 2500/5000 instrumentsprocess two Wells in parallel in48 seconds. Phadia 2500/5000provides the results at a 24seconds interval.</td><td colspan="1" rowspan="1">Phadia 250 needs one minuteto process one Well.Phadia 250 provides theresults at a one minuteinterval.</td></tr><tr><td colspan="1" rowspan="1">Daily throughput</td><td colspan="1" rowspan="1">About 2500/5000 tests</td><td colspan="1" rowspan="1">About 250 tests</td></tr></table>

\*Phadia 2500/5000 – Phadia 2500 and Phadia 5000 are identical instruments except for sample throughput. The difference is that Phadia 2500 consists of one process module (two process lines) and Phadia 5000 consists of 2 process modules ( $2 \mathrm { x } 2$ process lines). For that reason Phadia uses the Phadia 2500 and Phadia 5000 instrument names interchangeably.

# K. Standard/Guidance Document Referenced:

CLSI EP05-A3; Evaluation of Precision Performance of Quantitative Measurement Methods CLSI EP6-A Evaluation of the Linearity of Quantitative Measurement Procedures CLSI EP17-A2, Protocols for Determination of Limits of Detection and Limits of Quantification

# L. Test Principle:

The EliA wells are molded cups comparable to excised wells from a microtiter plate. They are made of polystyrene and are coated with the respective antigen.

The EliA wells are coated with human recombinant tissue transglutaminase for Celikey IgG, or with synthetic deamidated gliadin peptides for GliadinDP IgA and GliadinDP IgG. If present in the patient's specimen, antibodies to these proteins bind to the specific antigen. After washing away non-bound antibodies, enzyme-labeled antibodies against human IgA or IgG antibodies (EliA IgA Conjugate or EliA IgG Conjugate) are added to form an antibodyconjugate complex. After incubation, non-bound conjugate is washed away and the bound complex is incubated with a Development Solution. After stopping the reaction, the fluorescence in the reaction mixture is measured. The higher the response value, the more specific IgA or IgG is present in the specimen. To evaluate test results, the response for patient samples is compared directly to the response for calibrators.

# M. Performance Characteristics:

1. Analytical performance:

All results presented below met the manufacturer’s predetermined acceptance criteria.

a. Precision:

The imprecision of the assay was assessed in a study with a total of 21 runs (3 instruments $\times 7$ runs, 28 replicates/instrument/per sample) using serum native patient samples.

The studies were performed with 1 run/day over a period of 7 days. Each sample was tested in four replicates/run giving in total 84 replicates per sample. The data was calculated against the calibration curve from Day 1. The results are summarized in the table below:

EliA Celikey IgG on Phadia 2500/5000   

<table><tr><td rowspan=2 colspan=1>Mean(EliAU/mL)</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Between-run</td><td rowspan=1 colspan=2>Between-Instruments</td><td rowspan=1 colspan=2>TotalTotal Imprecision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>27.9</td></tr><tr><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>100.4</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>274.6</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>5.3</td></tr></table>

EliA GliadinDP IgA on Phadia 2500/5000   

<table><tr><td rowspan=2 colspan=1>Mean(EliA</td><td rowspan=2 colspan=2>Within-run</td><td rowspan=1 colspan=2></td><td rowspan=2 colspan=2>BetweenInstruments</td><td rowspan=2 colspan=2>TotalImprecision</td></tr><tr><td rowspan=1 colspan=2>Between run</td></tr><tr><td rowspan=1 colspan=1>U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>18.2</td></tr><tr><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>42.8</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>135.3</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>9.3</td></tr></table>

EliA GliadinDP IgG on Phadia 2500/5000   

<table><tr><td rowspan=1 colspan=1>Mean(EliA</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>BetweenInstruments</td><td rowspan=1 colspan=2>TotalImprecision</td></tr><tr><td rowspan=1 colspan=1>U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>13.0</td></tr><tr><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>73.7</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>8.1</td></tr><tr><td rowspan=1 colspan=1>219.6</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>17.0</td><td rowspan=1 colspan=1>7.7</td></tr></table>

# b. Linearity/assay reportable range:

Four patient serum samples were tested with one batch of EliA Celikey IgG, EliA GliadinDP IgA and EliA GliadinDP IgG Immunoassays and one set of system reagents on Phadia 2500/5000. The samples were serially diluted using the EliA Sample Diluent and tested in triplicates. The ratio of observed/expected (O/E) values were calculated. Observed values were graphed against the calculated values and a linear regression was performed. The results of the regression analysis are summarized below:

EliA Celikey IgG on Phadia 2500/5000   

<table><tr><td rowspan=1 colspan=1>Dilution range(EliA U/mL)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R{2</td></tr><tr><td rowspan=1 colspan=1>1.335.5</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>0.951.10</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>-0.711.69</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>1.82.9</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.931.11</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>0.692.07</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>2.296.6</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.981.06</td><td rowspan=1 colspan=1>1.68</td><td rowspan=1 colspan=1>-1.18 4.54</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>7.1174.0</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.971.05</td><td rowspan=1 colspan=1>2.26</td><td rowspan=1 colspan=1>-1.115.63</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>2.8227.8</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.981.10</td><td rowspan=1 colspan=1>2.48</td><td rowspan=1 colspan=1>2.757.72</td><td rowspan=1 colspan=1>0.99</td></tr></table>

The reportable range (Limit of Detection, upper limit) for EliA Celikey IgG is from 0.6–227 EliA $\mathrm { U } / \mathrm { m L }$ . The measuring range (Limit of Quantitation, upper limit) is from 1.7–227 EliA $\mathrm { U } / \mathrm { m L }$ .

EliA GliadinDP IgA on Phadia 2500/5000   

<table><tr><td rowspan=1 colspan=1>Dilution range(EliA U/mL)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>0.428.5</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.991.01</td><td rowspan=1 colspan=1>-0.04</td><td rowspan=1 colspan=1>-0.160.09</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>1.3137.8</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.951.02</td><td rowspan=1 colspan=1>-1.69</td><td rowspan=1 colspan=1>-3.390.00</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>0.6-26.9</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.98-1.02</td><td rowspan=1 colspan=1>-0.30</td><td rowspan=1 colspan=1>-0.54--0.05</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>2.1162.0</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.981.00</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.021.57</td><td rowspan=1 colspan=1>1.00</td></tr></table>

The reportable range (Limit of Detection, upper limit) and the measuring range (Limit of Quantitation, upper limit) for EliA GliadinDP IgA is from 0.4–142 EliA $\mathrm { U } / \mathrm { m L }$ . The measuring range (Limit of Quantitation, upper limit) is from 0.4 to 142 EliA $\mathrm { U } / \mathrm { m L }$ .

EliA GliadinDP IgG on Phadia 2500/5000   

<table><tr><td rowspan=1 colspan=1>Dilution range(EliA U/mL)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>0.6- 26.3</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.961.02</td><td rowspan=1 colspan=1>-0.32</td><td rowspan=1 colspan=1>-0.65 0.02</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>0.8-54.4</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.981.01</td><td rowspan=1 colspan=1>-0.50</td><td rowspan=1 colspan=1>0.86-0.13</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>7.0-334.9</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.921.03</td><td rowspan=1 colspan=1>-5.65</td><td rowspan=1 colspan=1>-13.852.56</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>7.3-288.3</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.991.01</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-0.312.35</td><td rowspan=1 colspan=1>1.00</td></tr></table>

The reportable range (Limit of Detection, upper limit) for EliA GliadinDP IgG is from 0.6 to 302 EliA $\mathrm { U } / \mathrm { m L }$ . The measuring range (Limit of Quantitation, upper limit) is from 1.4 to 302 EliA $\mathrm { U } / \mathrm { m L }$ .

The following statements are included in the package inserts: “Please note that concentration values between LoD and LoQ may show a higher uncertainty.” “Please note that due to differing binding characteristics of the antibodies in patient samples, not all sera can be diluted linearly within the measuring range.”

High dose hook effect: The hook effect was previously reviewed in the predicate devices (K062583 and K093459).

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The EliA IgG stability and calibration method was previously reviewed in K061165.

The EliA IgA stability and calibration method was previously reviewed in K062787.

# Controls:

Controls are sold separately from the assay. Calibrators are traceable to the International Reference Preparation (IRP) 67/86 of Human Serum Immunoglobulins A,G and M from World Health Organization (WHO).

# d. Detection limit:

The limit of blank (LoB), limit of detection (LoD), and limit of quantitation studies were performed on the Phadia 2500/5000 instrument. One blank sample was run in 33 replicates in two runs for a total of 66 observations. The LoD was measured by assaying three low level samples (11 replicates for each sample in each run) using two assay runs, for a total of 66 observations. Three additional low level samples were used for the LoD determination of the EliA Celikiey IgG for a total of 132 determinations.

The LoB and LoD were calculated according to CLSI guideline EP17-A2. To estimate the LoQ, a target level for the $C V \%$ of $20 \%$ has been defined. The mean value of the sample with the $C V \%$ closest to and below the precision target of $20 \%$ CV is selected as LoQ.

The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Phadia 2500/5000</td><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>EliACelikey IgG</td><td rowspan=1 colspan=1>EliA U/mL</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>EliAGliadinDPIgA</td><td rowspan=1 colspan=1>EliA U/mL</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>EliA GliadinDP IgG</td><td rowspan=1 colspan=1>EliA U/mL</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.4</td></tr></table>

e. Analytical specificity:

Interference: Previously reviewed in K062583 for CelikeyR IgG and in K093459 for GliadinDP IgA and IgG.

Carry-over: Phadia 2500/5000 instruments use disposable tips for pipetting samples and a separate pipette for the conjugate, therefore carry-over from samples to conjugate was not evaluated.

# f. Assay cut-off:

The three assays’ cut-offs are the same as in the predicate devices, K062583 CelikeyR IgG and in K093459 for GliadinDP IgA and $\mathrm { I g G }$ and are summarized in the table below:

<table><tr><td rowspan=1 colspan=2>EliA Celikey IgG, EliA GliadinDP IgA , EliA GliadinDP IgG</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 7 EliA U/mL</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>7 - 10 EliA U/mL</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>&gt; 10 EliA U/mL</td></tr></table>

2. Comparison studies:

a. Method comparison with predicate device: Instrument comparison was performed with the predicate device, see 2c below.

b. Matrix comparison:

Matrix comparison between serum and plasma was previously reviewed in K062583 for Celikey IgG and in K093459 for GliadinDP IgA and IgG.

c. Instrument comparison

The purpose of this study is to evaluate conformance and show comparability of the EliA assays on the instruments Phadia 250 (PH250) versus Phadia 2500/5000 (PH2500/5000). The samples were run in single replicates on one PH250 instrument and three PH2500/5000 (A, B, C) instruments for a total of four measurments per sample. Only samples inside the measuring range were included in the calculations. Results were analyzed by Passing-Bablock regression.

# EliA Celikey IgG:

100 samples were used in the study, 77 positive, 23 negative and 10 equivocal samples. The results are summarised below:

<table><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.260.73</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.910.94</td><td rowspan=1 colspan=1>0.998</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>-0.190.46</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.931.00</td><td rowspan=1 colspan=1>0.992</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 C</td><td rowspan=1 colspan=1>-0.28</td><td rowspan=1 colspan=1>0.55-0.00</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.971.00</td><td rowspan=1 colspan=1>0.998</td></tr></table>

Positive percent agreement (PPA), negative percent agreement (NPA), and total percent agreement (TPA) were evaluated with equivocal results considered positive in the table below:

<table><tr><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>PH2500/5000 C</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>96.1%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>90.9% - 99.7%</td><td rowspan=1 colspan=1>90.9% - 99.7%</td><td rowspan=1 colspan=1>89.0% - 99.2%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>82.6%</td><td rowspan=1 colspan=1>87.0%</td><td rowspan=1 colspan=1>91.3%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>61.2% - 95.0%</td><td rowspan=1 colspan=1>66.4%  97.2%</td><td rowspan=1 colspan=1>72.0% - 98.9%</td></tr><tr><td rowspan=1 colspan=1>TPA</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>95.0%</td><td rowspan=1 colspan=1>95.0%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>87.4% - 97.8%</td><td rowspan=1 colspan=1>88.7% - 98.4%</td><td rowspan=1 colspan=1>88.7% - 98.4%</td></tr></table>

Results when equivocal results are considered negative are presented in the table below:

<table><tr><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>PH2500/5000 C</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>95.5%</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>94.0%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>87.5% - 99.1%</td><td rowspan=1 colspan=1>89.6%- 99.6%</td><td rowspan=1 colspan=1>85.4% - 98.3%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>89.4% - 100%</td><td rowspan=1 colspan=1>89.4% - 100%</td><td rowspan=1 colspan=1>89.4% - 100%</td></tr><tr><td rowspan=1 colspan=1>TPA</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>96.0%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>91.5% - 99.4%</td><td rowspan=1 colspan=1>93.0% - 99.8%</td><td rowspan=1 colspan=1>90.1% - 98.9%</td></tr></table>

EliA GliadinDP IgA:

105 samples were used in the study, 79 positive, 21 negative and 5 equivocal samples.The results are summarised below:

<table><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.400.93</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.920.98</td><td rowspan=1 colspan=1>0.993</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>0.280.83</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.951.00</td><td rowspan=1 colspan=1>0.994</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 C</td><td rowspan=1 colspan=1>-0.24</td><td rowspan=1 colspan=1>-0.710.06</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>1.061.11</td><td rowspan=1 colspan=1>0.994</td></tr></table>

Positive percent agreement (PPA), negative percent agreement (NPA), and total percent agreement (TPA) were evaluated with equivocal results considered positive in the table below:

<table><tr><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>PH2500/5000 C</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>95.7% - 100%</td><td rowspan=1 colspan=1>95.7% - 100%</td><td rowspan=1 colspan=1>95.7% - 100%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>90.5%</td><td rowspan=1 colspan=1>85.7%</td><td rowspan=1 colspan=1>90.5%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>69.6% - 98.8%</td><td rowspan=1 colspan=1>63.7% - 97.0%</td><td rowspan=1 colspan=1>69.6% - 98.8%</td></tr><tr><td rowspan=1 colspan=1>TPA</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>98.1%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>93.3% - 99.8%</td><td rowspan=1 colspan=1>91.9% - 99.4%</td><td rowspan=1 colspan=1>93.3% - 99.8%</td></tr></table>

Results when equivocal results are considered negative are presented in the table below:

<table><tr><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 A</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>98.7%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>93.2% - 100%</td><td rowspan=1 colspan=1>95.4% - 100%</td><td rowspan=1 colspan=1>93.2% - 100%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>96.2%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>80.4% - 99.9%</td><td rowspan=1 colspan=1>80.4% - 99.9%</td><td rowspan=1 colspan=1>80.4% - 99.9%</td></tr><tr><td rowspan=1 colspan=1>TPA</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>98.1%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>93.3% - 99.8%</td><td rowspan=1 colspan=1>94.8% - 100%</td><td rowspan=1 colspan=1>93.3% - 99.8%</td></tr></table>

EliA GliadinDP IgG:

104 samples were used in the study, 80 positive, 19 negative and 5 equivocal samples.The results are summarised below:

<table><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>R</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>-0.14</td><td rowspan=1 colspan=1>-0.410.13</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>1.041.09</td><td rowspan=1 colspan=1>0.997</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.131.16</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.941.02</td><td rowspan=1 colspan=1>0.994</td></tr><tr><td rowspan=1 colspan=1>PH2500/5000 C</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>-0.200.20</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>1.071.10</td><td rowspan=1 colspan=1>0.998</td></tr></table>

Positive percent agreement (PPA), negative percent agreement (NPA), and total percent agreement (TPA) were evaluated with equivocal results considered positive in the table below:

<table><tr><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>PH2500/5000 C</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>95.8% - 100%</td><td rowspan=1 colspan=1>95.8% - 100%</td><td rowspan=1 colspan=1>95.8% - 100%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>89.5%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>94.7%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>66.9% - 98.7%</td><td rowspan=1 colspan=1>82.4% - 100.0%</td><td rowspan=1 colspan=1>74.0% - 99.9%</td></tr><tr><td rowspan=1 colspan=1>TPA</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>99.0%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>93.2% - 99.8%</td><td rowspan=1 colspan=1>96.5% - 100%</td><td rowspan=1 colspan=1>94.8% - 100%</td></tr></table>

Results when equivocal results are considered negative are presented in the table below:

<table><tr><td rowspan=1 colspan=1>Criteria</td><td rowspan=1 colspan=1>PH2500/5000 A</td><td rowspan=1 colspan=1>PH2500/5000 B</td><td rowspan=1 colspan=1>PH2500/5000 C</td></tr><tr><td rowspan=1 colspan=1>PPA</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>93.2% - 100%</td><td rowspan=1 colspan=1>95.5%- 100%</td><td rowspan=1 colspan=1>95.5% - 100%</td></tr><tr><td rowspan=1 colspan=1>NPA</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>95.8%</td><td rowspan=1 colspan=1>91.7%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>85.8% - 100%</td><td rowspan=1 colspan=1>78.9%  99.9%</td><td rowspan=1 colspan=1>73.0% - 99.0%</td></tr><tr><td rowspan=1 colspan=1>TPA</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>98.1%</td></tr><tr><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>94.8% - 100%</td><td rowspan=1 colspan=1>94.8% - 100%</td><td rowspan=1 colspan=1>93.2% - 99.8%</td></tr></table>

3. Clinical studies:

Clinical performance was previously reviewed in Previously reviewed in K062583 for CelikeyR IgG and in K093459 for GliadinDP IgA and $\mathrm { I g G }$ .

4. Clinical cut-off: See assay cut-off

5. Expected values/Reference range:

A total of 400 apparantly healthy Caucasian blood donors matched by age and sex were tested on the Phadia 2500/5000 instrument to evaluate expected values in the normal population. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Test(n=400)</td><td rowspan=1 colspan=1>Mean(EliA U/mL)</td><td rowspan=1 colspan=1>Median(EliA U/mL)</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>95thpercentile</td><td rowspan=1 colspan=1>99thpercentile</td></tr><tr><td rowspan=1 colspan=1>EliA Celikey IgG</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.16.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>EliA GliadinDP IgA</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.0-16.1</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>EliA GliadinDP IgG</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.151.5</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>13.3</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.